



8th IISPV SCIENTIFIC SESSION 2021

"Lessons from COVID-19: What have we learned and questions remaining"



2 June, 2021 - 3.30 pm 3 June, 2021 - 10.30 am

(online edition)

2 June, 2021

3.30 pm – Welcome, Joan Vendrell i Ortega, IISPV Director

Chairs: Elisabet Vilella and Laia Reverté

Plenary session

3.40 pm — **Advances in COVID-19 Drug Therapy. Roger Paredes**. Section Chief, Infectious Diseases Department, Institut de Recerca de la SIDA-irsiCaixa. Adjunct Associate Professor, Center for Global Health and Diseases, Department of Pathology. Hospital U. Germans Trias i Pujol.

IISPV Researcher's session

- 4.20 pm COVID19-related and all-cause deaths among people over 50 years during the first epidemic wave in Tarragona, March-June 2020. **Cinta de Diego** (Wellbeing and Disease Prevention Transversal Program).
- 4.30 pm Circulating and cellular prognostic biomarkers for COVID-19 progression in patients with SARS-CoV-2 infection using multi-omic science. Laia Reverté (Infection and Immunity (INIM) research group).
- 4.40 pm Closing remarks, **Elisabet Vilella**, IISPV Leadership Committee.

3 June, 2021

10.30 am – Welcome, **Joan Vendrell i Ortega**, IISPV Director

Chairs: Mònica Bulló and Christopher Papandreu

Plenary session

10.35 am — Living with Obesity Increases Risks of COVID-19. Jason CG Halford. Head of the School of Psychology at the University of Leeds, President Elect of the European Association of Obesity (EASO), and former Chair of the UK Association for the Study of Obesity (ASO).

11.30 am — **Crònica d'una pandèmia anunciada. Model matemàtic. Alexandre Arenas.** Professor of complex systems. Director of the Chair of Science and Humanism. Department of computer engineering and mathematics. URV.

IISPV Researcher's session

- 12.20 am Comparing eating behaviors, and symptoms of depression and anxiety between Spain and Greece during the COVID-19 outbreak: Cross-sectional analysis of two different confinement strategies. **Christopher Papandreu** (IISPV Researcher).
- 12.30 am Susceptibility and risk of SARS-COV-2 Infection among middle aged and older adults in Tarragona area (Objective: To analyze susceptibility/risk of suffering COVID-19 among adults with distinct underlying medical conditions). **Eva Ma. Satue** (Wellbeing and Disease Prevention Transversal Program).
- 12.40 am Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2,022 critically ill patients with COVID-19 in Spain and impact of corticosteroids treatment in whole population and each phenotype derived. **Alejandro Rodríguez** (SEPSIS, Inflammation and Safety of the critically ill).
- 12.50 am Closing remarks, **Elisabet Vilella**, IISPV Leadership Committee.